Correction to: Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects.
Romito I, Porru M, Braghini MR, Pompili L, Panera N, Crudele A, Gnani D, De Stefanis C, Scarsella M, Pomella S, Mortera SL, de Billy E, Conti AL, Marzano V, Putignani L, Vinciguerra M, Balsano C, Pastore A, Rota R, Tartaglia M, Leonetti C, Alisi A.
Romito I, et al.
J Exp Clin Cancer Res. 2022 Jan 27;41(1):40. doi: 10.1186/s13046-022-02247-y.
J Exp Clin Cancer Res. 2022.
PMID: 35086550
Free PMC article.
No abstract available.